World Allergy Forum - IgE: Bench to Bedside
Allen P. Kaplan
March 2, 2002
As President of World Allergy Organization-IAACI (WAO) it is my pleasure to be present at the 58th Annual Meeting of the American Academy of Allergy, Asthma & Immunology, and bring you the 18th symposium in a series of World Allergy Forums presenting state-of-the-art programs at major allergy conventions around the world.
World Allergy Organization-IAACI is the rapidly expanding global umbrella organization representing 58 national and regional allergy and clinical immunology societies. A major role of WAO is the development of educational programs in allergy and clinical immunology for our member societies, and for outreach presentations to professional medical organizations that have a strong interface with our specialty.
WAO is recognized by World Health Organization to be the major global voice of allergy. The importance of allergen exposure and immunological sensitization to the development of asthma, has led to a collaboration between WAO and WHO on a WHO Technical Document, Prevention of Allergy and Asthma. Against this background of increasing global awareness of the role of atopy in the development of asthma, "IgE: Bench to Bedside" is an important addition to the WAO educational portfolio. I sincerely thank the American Academy of Allergy, Asthma andd Immunology for enabling us to bring this program to you.
Upcoming programs in the World Allergy Forum series will address the underlying pathology of allergic disease, and look at the difficult-to-manage cases that may have multiple components to their etiology. The development of anti-IgE monoclonal antibodies is a major breakthrough in therapy for allergic rhinitis and asthma. Allergists and pulmonologists alike are eager to learn about this new therapy as it enters our therapeutic armamentarium.
Future modules of this program will look not only at this exciting development, and its role in combination with currently available therapies, but also at other novel anti-allergic therapies and their potential applications, particularly those which have the potential to treat multiple concomitant allergic diseases.
I hope you will enjoy this symposium and the presentations of our excellent faculty.
Allen P. Kaplan
President, World Allergy Organization
Michael A. Kaliner
March 2, 2002
On behalf of the World Allergy Organization - IAACI (WAO), it is a great pleasure to welcome you to this World Allergy Forum symposium, during which internationally renowned speakers will address the subject of IgE.
Few advances in medicine have caused as much excitement as the advent of the availability of anti-IgE as a therapeutic tool in the treatment of allergic diseases, including asthma. Allergists have long known that allergy is important in many asthmatics, as well as critical in the causation of allergic rhinitis, food allergy, eczema and anaphylaxis. The ability to reduce circulating IgE with a monoclonal antibody, with the consequent reduction in cell-bound IgE and reduction in the allergic response, led to clinical experiments which demonstrated the usefulness of this approach in asthmatics and rhinitics. Ongoing experiments are looking at food allergy and immunotherapy.
This symposium will trace the role of anti-IgE through the basic science to the applied clinical science of its use, and prepare those attending for what will be a most exciting era in the treatment of allergic disease.
We look forward to four excellent lectures, and to lively interaction with you during the discussion period which will follow each presentation.
WAO sincerely acknowledges the unrestricted educational grant provided by Novartis to facilitate this event.
Michael A. Kaliner, MD